超声造影提高O-RADS超声风险分层系统对恶性肿瘤的诊断效能
前瞻性研究纳入2018年5月至2021年3月于手术前接受超声造影且超声分类为O-RADS 3、4或5类的病变,以组织病理学为参考标准建立联合诊断模型,并在2021年4月至2022年7月独立的验证组中验证。彩超造影评分≥4分时O-RADS风险分层上调一级,≤2分时下调一级;验证组中O-RADS联合超声造影评分的AUC为0.93,高于单用O-RADS的0.71(P < .001)。
要点
- O-RADS 3–5类病变中,超声造影初始增强时间、增强强度及动态变化在良恶性间差异有统计学意义(P < .001)。
- 超声造影评分≥4分将O-RADS上调一级,≤2分下调一级。
- 验证组联合评分AUC为0.93,高于单用O-RADS的0.71(P < .001)。
核心结论
- 超声造影提高了O-RADS 3–5类病变对恶性肿瘤的诊断效能。
研究设计与样本
- 前瞻性研究; pilot组76例女性(平均年龄44岁±13[SD]),验证组46例女性(平均年龄42岁±14);以组织病理学为参考标准。
关键影像表现/征象
- 评估了与子宫肌层比较的初始增强时间、增强强度、造影剂分布模式及病灶增强的动态变化。
- 良恶性病变间初始增强时间(P < .001)、增强强度(P < .001)及增强动态变化(P < .001)差异有统计学意义。
诊断标准与关键数值
- 超声造影评分用于判定良性(评分≤2)与恶性(评分≥4)病变。
- 超声造影评分≥4分时O-RADS风险分层上调一级,≤2分时下调一级。
- 验证组O-RADS联合超声造影评分AUC为0.93,高于单用O-RADS的AUC 0.71(P < .001)。
临床应用与阅片要点
- 对超声分类为O-RADS 3、4或5类的病变,可结合超声造影评分调整O-RADS风险分层。
- 超声造影评分≥4分上调一级、≤2分下调一级,用于辅助鉴别良恶性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Ovarian-Adnexal Reporting and Data System (O-RADS) has limited specificity for malignancy. Contrast-enhanced US can help distinguish malignant from benign lesions, but its added value to O-RADS has not yet been assessed. Purpose To establish a diagnostic model combining O-RADS and contrast-enhanced US and to validate whether O-RADS plus contrast-enhanced US has a better diagnostic performance than O-RADS alone. Materials and Methods This prospective study included participants from May 2018 to March 2021 who underwent contrast-enhanced US before surgery and had lesions categorized as O-RADS 3, 4, or 5 by US, with a histopathologic reference standard. From April 2021 to July 2022, participants with pathologically confirmed ovarian-adnexal lesions were recruited for the validation group. In the pilot group, the initial enhancement time and enhancement intensity in comparison with the uterine myometrium, contrast agent distribution pattern, and dynamic changes in enhancement of lesions were assessed. Contrast-enhanced US features were used to calculate contrast-enhanced US scores for benign (score ≤2) and malignant (score ≥4) lesions. Lesions were then re-rated according to O-RADS category plus contrast-enhanced US scores. Receiver operating characteristic curves were constructed and compared using the DeLong method. The combined system was validated in an independent group. Results The pilot group included 76 women (mean age, 44 years ± 13 [SD]), and the validation group included 46 women (mean age, 42 years ± 14). Differences in initial enhancement time (P < .001), enhancement intensity (P < .001), and dynamic changes in enhancement (P < .001) between benign and malignant lesions were observed in the pilot group. Contrast-enhanced US scores were calculated using these features. The O-RADS risk stratification was upgraded one level for contrast-enhanced US scores of 4 or more and downgraded one level for contrast-enhanced US scores of 2 or less. In the validation group, the diagnostic performance of O-RADS plus contrast-enhanced US score was higher (area under the receiver operating characteristic curve [AUC] = 0.93) than O-RADS (AUC = 0.71, P < .001). Conclusion Contrast-enhanced US improved the diagnostic performance for malignancy of the O-RADS categories 3-5. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Grant in this issue.
引用
- Yuan K, Huang YJ, Mao MY, et al. Contrast-enhanced US to Improve Diagnostic Performance of O-RADS US Risk Stratification System for Malignancy. Radiology. 2023. PMID: 37552073. doi:10.1148/radiol.223003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。